Compare FirstEnergy Corp. (FE) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Novartis AG — how do they compare? FirstEnergy Corp. trades at $45 (market cap $25.95B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 10.3× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (4.15%). Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Novartis AG for 82 Days on average.
| FE | NVS | |
|---|---|---|
Market Cap | $25.95B | $268.57B |
Volume | 5,643,833 | 1,532,573 |
Sector | Utilities | Health |
52-Week High | $51.91 | $168.62 |
52-Week Low | $43.04 | $121.80 |
Typical Hold Time | 71 Days | 82 Days |
Enterprise Value | $54.87B | $309.89B |
Dividend Yield | 4.15% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% today, with a bullish technical signal but mixed earnings history. Revenue grew to $15.09B in 2025, with a net income margin of 6.86%, while valuation ratios like P/E of 23.84 and P/S of 1.63 suggest moderate pricing. Recent news highlights dividend declarations and a $36B Energize365 investment plan, supporting long-term growth amid rising data-center demand.
Outlook is positive with a consensus price target of $52.80, implying 18% upside, but risks include high debt levels and volatile cash flows. Analyst sentiment is mixed with 43% buy ratings, while institutional ownership trends show recent stake increases, indicating cautious optimism for steady utility returns.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
